Try our Advanced Search for more refined results

Anthony Basile et al v. Valeant Pharmaceutical International, Inc. et al

  1. January 29, 2018

    Investors Seek Early OK For $290M Valeant, Pershing Deals

    Investors who sued Pershing Square Capital Management LP and Valeant Pharmaceuticals over their alleged insider trading scheme ahead of Valeant's failed $55 billion effort to acquire Allergan Inc. filed papers Friday to begin the approval process for $290 million in settlements.

  2. January 02, 2018

    Pershing, Valeant Agree To $290M Deal Ending Allergan Suits

    Hedge fund Pershing Square and Valeant Pharmaceuticals have reached a $290 million preliminary agreement to settle two investor suits in California federal court accusing them of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan.

  3. November 07, 2017

    Investors Spar Over Damages In Valeant, Pershing Rows

    Investors behind two suits accusing Valeant Pharmaceuticals and hedge fund Pershing Square of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan Inc. duked it out in California federal court Monday over proposals for how to handle potentially competing damages awards in their respective cases.

  4. August 15, 2017

    Investors Seek To Strike Part Of Pershing's Quick Win Bid

    Investors behind a class action accusing Valeant Pharmaceuticals and hedge fund Pershing Square of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan Inc. urged a California federal court on Monday to strike three pages about the U.S. Securities and Exchange Commission from a recent Pershing brief as "irrelevant, immaterial, impertinent and inadmissible."

  5. July 11, 2017

    Valeant, Pershing, Investors Battle For Quick Wins In Suit

    Valeant Pharmaceuticals and hedge fund Pershing Square Capital Management LP sought quick wins Monday in an investor suit accusing the firms of insider trading, telling a California federal court that the firms' collaboration on Valeant's attempted $55 billion takeover of Allergan was "legitimate group activity."

  6. July 05, 2017

    Valeant, Pershing Trying To Hide Behind SEC, Investors Say

    Investors behind a class action accusing hedge fund Pershing Square and Valeant Pharmaceuticals of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan Inc. have told a California federal court that the two firms are wrongly trying to use the U.S. Securities and Exchange Commission as a shield.

  7. May 16, 2017

    Valeant, Pershing Square Balk At Draft Class Action Notices

    Valeant Pharmaceuticals and Pershing Square Capital Management LP have objected to the notification procedures proposed in a newly certified class action over insider trading claims related to an attempted $55 billion takeover of Allergan Inc., telling a California federal court on Monday that the investors behind the suit aren't giving derivative traders an adequate chance to participate.

  8. March 15, 2017

    Allergan Investors Win Cert. In Valeant Insider Trading Row

    A California federal judge on Wednesday granted class certification in a stock-drop suit against Valeant Pharmaceuticals and William Ackman's Pershing Square Capital Management LP over an attempted $55 billion takeover of Allergan Inc., saying Allergan investors who sold their stock have alleged common losses that bind them together.

  9. February 13, 2017

    Valeant, Ackman Ink Allergan Litigation Management Deal

    Valeant Pharmaceuticals International Inc. and William Ackman's hedge fund Pershing Square Capital Management have agreed to split litigation costs in a putative class action over an alleged insider trading scheme in 2014's Allergan takeover bid, according to a filing made Monday with the U.S. Securities and Exchange Commission.

  10. December 21, 2016

    Bernstein Litowitz Ducks Subpoena In Insider Trading Row

    A California federal special master has denied an email subpoena bid by Pershing Square Capital Management LP against Bernstein Litowitz Berger & Grossmann LLP, which represents investors alleging that Valeant Pharmaceuticals International Inc. illegally tipped Pershing Square to a proposed merger.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!